Photo: Russian Health Ministry


The manufacturers of the Russian Sputnik V, which according to recent late stage trial results published in the British medical journal The Lancet offers nearly 92 percent protection against the coronavirus, is now looking to produce its vaccine in Mexico, according to Kirill Dmitriev, head of the Russian Foundation for Direct Investment.

“Sputnik V is searching for a Mexican partner to produce the vaccine in Mexico in the medium term,” Dmitriev said in a video press conference Monday, Feb. 22.

“We are currently in conversations with various Mexican pharmaceutical firms.”

Dmitriev went on to say that 20 companies worldwide are already working with Russia to produce the vaccine, including in South Korea, India, China and Brazil.

“We hope that Mexico will join that list,” he said, adding that Russia expected to have a formal agreement with a Mexican partner by March of this year.

The Sputnik V vaccine was granted emergency approval for use in Mexico earlier this month.

Mexico is currently working with Argentina in the bottling of the AstraZenica vaccine produced in that South American country, but is not producing any covid vaccines domestically.

The two-dose Sputnik vaccine has certain advantages, especially in countries with limited infrastructure, because it is easier to distribute and manage than the AstraZenica and Pfizer vaccines since it does not require extreme refrigeration.

Although the Sputnik V was initially met with some controversy after being rolled out before the final trial data had been released, the publication in The Lancet earlier this month and subsequent peer review allowed it to join the ranks of internationally proven

…Feb. 24, 2021

Leave a Reply